Wall Street closes at a record for the first time since end of January
OrbiMed Advisors LLC, a ten percent owner in Adicet Bio, Inc. (NASDAQ:ACET), reported selling 104,259 shares of common stock in the company. The sales occurred on April 7 and April 8, 2026, with prices ranging from $6.29 to $6.53, totaling approximately $674,847.
On April 7, OrbiMed sold 29,319 shares at $6.53 and 2,400 shares at $6.38. On April 8, the entity sold 32,523 shares at $6.29 and 40,416 shares at $6.52.
Following these transactions, OrbiMed Advisors still indirectly holds a significant number of Adicet Bio shares through various entities including OrbiMed Israel Partners Limited Partnership, OrbiMed Genesis Master Fund, L.P., OrbiMed Private Investments V, LP, and OrbiMed Private Investments VI, LP.The stock currently trades at $6.86, near its 52-week low of $6.01, following a 53% decline over the past six months. Despite this volatility, InvestingPro analysis suggests the company appears undervalued at current levels, with a Fair Value estimate indicating potential upside. For deeper insights, investors can access a comprehensive Pro Research Report on ACET, one of 1,400+ available US equities.
In other recent news, Adicet Bio has been the subject of several analyst updates. H.C. Wainwright adjusted its price target for Adicet Bio, first raising it to $50 from $9 due to anticipated progress in the company’s CD20-targeted allogeneic gamma delta CAR-T cell therapy, prulacabtagene leucel. However, the same firm later lowered the price target to $27, citing a higher discount rate and increased long-term operating expenses, though it maintained a Buy rating. In addition, Guggenheim also revised its price target for Adicet Bio, reducing it from $128 to $100 while keeping a Buy rating. The firm highlighted strong enrollment momentum in Adicet Bio’s Phase 1 trial for prula-cel, targeting various autoimmune conditions. Clinical updates for this trial are expected in 2026. These developments indicate ongoing interest and activity in Adicet Bio’s therapeutic advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.